BEAM-302

Beam Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	BEAM-302
Sponsor	Beam Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BEAM-302 CI brief — competitive landscape report
BEAM-302 updates RSS · CI watch RSS
Beam Therapeutics Inc. portfolio CI